Work

746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

Year: 2020

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.818

Authors: P. O'Donnell, M.D. Galsky, J.E. Rosenberg, D.P. Petrylak, A.V. Balar, B.A. McGregor, E. Heath, E.Y. Yu, D.I. Quinn, N.M. Hahn, M. Campbell, S-Y. Liang, J. Steinberg, Y. Loriot

Institutions: University of Chicago, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Yale University, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of Washington, University of Southern California, Johns Hopkins University, Johns Hopkins Medicine, Seagen (United States), Astellas Pharma (United States), Institut Gustave Roussy

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3088099732

FWCI: 1.435

Cites:

Cited by: 11

Related to: 10